Literature DB >> 6143976

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).

T Higenbottam, D Wheeldon, F Wells, J Wallwork.   

Abstract

A young woman, bedbound with severe pulmonary hypertension, responded to intravenous epoprostenol with a fall in pulmonary vascular resistance, improved oxygenation, and a rise in exercise tolerance. For thirteen months, continuous infusion of epoprostenol has enabled her to live independently at home.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143976     DOI: 10.1016/s0140-6736(84)91452-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension.

Authors:  R Ziesche; V Petkov; K Wittmann; J Kopatschka; L Stiebellehner; P Schenk; P Germann; G Röder; R Ullrich; L H Block
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

Review 4.  Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.

Authors:  Yaguo Zheng; Tao Yang; Guo Chen; Enci Hu; Qing Gu; Changming Xiong
Journal:  Eur J Clin Pharmacol       Date:  2013-09-12       Impact factor: 2.953

Review 5.  Pulmonary hypertension-"state of the art" management in 2012.

Authors:  Anita Saxena
Journal:  Indian Heart J       Date:  2012-03-26

6.  Thromboembolism in primary pulmonary hypertension.

Authors:  A Bishop; P Oldershaw
Journal:  BMJ       Date:  1996-12-07

7.  Primary pulmonary hypertension.

Authors:  T Higenbottam
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

8.  Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension.

Authors:  N Nagaya; Y Shimizu; T Satoh; H Oya; M Uematsu; S Kyotani; F Sakamaki; N Sato; N Nakanishi; K Miyatake
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

9.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

Review 10.  Genomics of pulmonary arterial hypertension: implications for therapy.

Authors:  Mark W Geraci; Todd M Bull; Rubin M Tuder
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.